Physician profile
Daniel P Hill
NPI 1659358711
$3,775.97
in general payments reported to CMS, 2019-2025
36 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $192 · 2021: $780 · 2022: $470 · 2023: $270 · 2024: $344 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $624.66 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $494.27 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $365.04 | 2019-2025 | |
| Amarin Pharma, INC. | $247.98 | 2019-2021 | |
| Amgen INC. | $227.70 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.77 | 2019-2022 | |
| Abbvie INC. | $204.04 | 2021-2025 | |
| Glaxosmithkline, LLC. | $173.97 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $141.79 | 2019-2020 | |
| Abbott Laboratories | $139.36 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $94.11 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $87.94 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Mylan Specialty L.P. | $85.00 | 2021 | |
| Novo Nordisk INC | $80.29 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $51.75 | 2019 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.